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Abstracts / Biol Blood Marrow Transplant 19 (2013) S313eS341 S317with an observed FEV1 < 90% or FEF 25-75 < 75% were
recorded, and compared to the recorded date of BOS diag-
nosis. Fisher's exact test was applied to determine statistical
signiﬁcance where applicable.
Results: For all BOS patients, the mean time from trans-
plantation to diagnosis of BOS was 478 days (95% CI
357-599d) compared to amean time of 169 days (95% CI 100-
238d) when patients had either an FEV1<90% or FEF25-75
<75%. The mean difference was 298 days (95% CI 176-420d,
P ¼ .00003). Patients with cGVHD and no BOS had similar
decline in PFT in only 22/44 patients, compared to 100% of
those with BOS. Serum IGF-1 values were > 4,000 (25th
percentile) in 12 of 13 patients with BOS (P ¼ .04). Overall, 12
of 13 patients had biomarkers elevation prior to spirometric
diagnosis of BOS.
Conclusions: Application of the BOS 0-p criteria to HSCT
patients may identify patients at risk for BOS at an earlier
time point. The use of the IGF 1 as a serum biomarker may
also contribute to identify patients at risk, although further
studies are needed to investigate whether this marker can
differentiate between patients with BOS and those with
other lung diseases.417
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Haploidentical (HI) HSCT with low dose donor T-cell infusion
provides a survival advantage in tumor bearing mice when
compared to parent F1 or MHC-matched transplant models.
We suggest thatMHC difference in HI-HSCTgenerates early T-
cell clonal activation against the unshared MHC haplotype,
which eliminates residual tumor cells that express the
unsharedMHChaplotype.However, alteration inMHCantigen
expression is a signiﬁcant contributor to tumor escape from
graft-versus-tumor (GVT) activity. Recent haploidentical
transplant data revealed that uniparental disomy, the loss of
theHLAhaplotype, is a clinically relevantmechanismof tumor
escape that leads to post-transplant leukemia relapse. Murine
renal cell carcinoma, RENCA cell line normally expresses only
H2Kdas a MHC molecule. Therefore, in our haploidentical
transplant model, T cell clonal activity is usually restricted
against H2Kdmolecule only. For circumventing the single
haplotype expression of tumormodel, we transfected this cell
line with a H2Kbexpressing vector, pAcGFP-NeoR-H2Kb, and
generatedstable cloneswithG418 selection. The clone thathas
more than 95% H2Kbexpression used for in vivo experiments.
Both tumor cell lines, i.e. parental and transfected clone, had
similar in vivo tumor growth acceptance and growth rate. We
then used two different haploidentical donors that were tar-
geting different MHC haplotypes. Lethally irradiated B6D2F1
(H2Kb/d) mice were transplanted with T cell depleted bone
marrow(TCD-BM) fromeitherB6C3F1(H-2Kb/k) (singlehaplo-
1; SH1), or C3D2F1 (H2Kk/d) (single haplo 2; SH2) or both
donor mice with low-dose (1x105) T-cells. In some experi-
ments, animals were also injected either H2Kdor H2Kb/
d expressingRENCA-TGL cells for the evaluationofGVTactivity
Bone marrow (BM), spleens and thymi were harvested from
recipients of single and double HI-HSCT at day 35 and
showed similar cellularities. Interestingly, spleen and bonemarrow had similar chimerism from both donors in DH-
HSCT. There were no early transplant mortality, graft failure,
weight loss and GVHD scoring difference among the double
or single-haploidentical transplant recipients. In two other
sets of experiments, we followed the tumor growth and the
survival of tumor bearing mice after transplant. The recipi-
ents of DH-HSCT showed a better survival and GVT activity
than the recipients of SH-HSCT in RENCA-TGL (H2Kb/d)
bearing tumor model. These observations conﬁrmed that
MHC targeting plays a prominent role in tumor surveillance,
and immune targeting the unshared MHC haplotype with
haploidentical transplant induce remarkable survival
advantage.418
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Background: The most widely used mice model of chronic
graft-versus-host disease (cGvHD) is an MHC-matched bone
marrow transplantation model of sclerodermatous cGvHD. A
limitation of that model is that mortality is relatively low,
making difﬁcult to study the impact of potentially thera-
peutic compounds.
Aims: To develop a more severe model of cGVHD and to
assess the impact of Rapamycin administration in that
model.
Results: Lethally irradiated Balb/C mice were injected with
10x106 bone marrow cells and 70x106 splenocytes from
B10.D2 donor mice. Twenty-one days later, all mice devel-
oped cGvHD. For the severe model, donor B10.D2 mice were
injected with 0.5x106 splenocytes from Balb/C twenty-one
days before transplantation. All mice from the severe model
(n¼8) died a median of 32 days while 3 of 7 mice in the
classical model survived beyond day 52. Mean survival was
decreased in the severe model compared to the classical
model (32 days versus 37 days; p¼0.0185). Recipient mice in
the severe group experienced higher weight loss, hair loss
and skin ﬁbrosis. Numbers of T lymphocytes (251.9  151.4
versus 626.3  532.8; p¼0.0004) and CD4+ T cells (61.57 
41.93 versus 125.0  14.39; p¼0.0008) per microliter of
blood at day 21 were lower in the severe group than in the
classical model. Moreover, number of regulatory T cells
(Tregs) was decreased in the severe model (0.9870  0.8864
versus 7.979  6.753; p¼0.0062).
We then investigated whether rapamycin administration
could prevent GVHD in the severe model. All (n¼8) mice
treated with PBS (placebo) died a median of 32 days after
transplantation, while 6 of 8 mice given 1mg/kg/day i.p.
rapamycin survived beyond day 52 (p¼0.0012). Number of
Tregs/ml was higher at day 21 in rapamycin-treatedmice than
in mice given PBS (3.532  1.195 versus 1.958  0.8864;
p¼0.0796). Moreover, number of naïve CD4+T (7.798  4.192
versus 25.71  5.185; p¼ 0.0276), effector memory CD4+ T
cells (EMT) (40.50  3.180 versus 25.17  7.881; p¼ 0.0392)
and central memory CD4+ T cells (CMT) (53.58 3.180 versus
26.29  7.881; p¼ 0.0060) were higher in rapamycin mice.
Finally, proliferation of EMT (assessed by ﬂow cytometry
using Ki-67) (34.70%  4.084 versus 30.80%  2.003;
p¼0.0221) and CMT (33.25%  4.084 versus 27.50%  2.003;
p¼0.0183) was higher in PBS than in rapamycin mice.
